TAVI is increasingly being used to treat patients at intermediate risk for surgical mortality who require aortic valve replacement. However, patients undergoing valve replacement face increased risk of death and long-term morbidity due to periprocedural stroke after either transcatheter or surgical valve replacement procedures.
"As TAVI moves into lower-risk patients, it's important to understand the relative risk for neurological complications following surgical aortic value replacement and TAVI," explained the lead author of the SURTAVI trial, Pieter Kappetein, Professor in Cardiothoracic Surgery at Erasmus Medical Center, Rotterdam, the Netherlands.
The trial randomised 1,660 patients with severe, symptomatic aortic stenosis and at intermediate surgical risk to aortic valve replacement with TAVI or surgery. A neurologist or stroke specialist evaluated any patient who had a suspected neurological event after their procedure.
Results showed that the incidence of early stroke at 30 days was significantly lower in patients undergoing TAVI (3.3%) than in those having surgical aortic valve replacement (5.4%, p=0.031). Stroke incidence remained lower at two years with TAVI compared to surgery (6.3% vs. 8.0%, p=0.143). One-year mortality was similar for TAVI and surgery patients with stroke or with encephalopathy at 30 days.
"Surgical aortic valve replacement carries a higher risk in intermediate-risk patients and TAVI might be the preferred treatment in patients with aortic stenosis," suggested Kappetein. He said, "This is the first time that there has been shown to be a lower stroke rate with TAVI compared to surgery," adding that the findings will change practice.
Further results showed that quality of life, based on the SF-36 physical summary, was lower at 30 days for all patients with early stroke compared to those not having a stroke. Quality of life improved more quickly in TAVI patients with stroke but was similar by six months regardless of procedure type.
Contact: Pieter Kappetein, Erasmus Medical Center, Rotterdam, the Netherlands
EuroPCR 2017 session: Thursday 18 May 09:45-10:45, Hot Line/Late-breaking Trials, Coronary interventions, interventions for valvular disease, CTO, STEMI, Stents and scaffolds, TAVI; Main Arena
Help for journalists to cover EuroPCR 2017
For any press-related inquiries, please contact:
EuroPCR Press Coordinator, Isabelle Uzielli email@example.com
Register and attend EuroPCR 2017 as a journalist
Press registration for EuroPCR is open to accredited journalists, free of charge. Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press go to https://www.pcronline.com/Courses/EuroPCR/EuroPCR-2017/Press
EuroPCR press releases
EuroPCR press releases can be found at https://www.pcronline.com/News/Press-releases?date=2017
Attend press briefings
For the press briefing schedule check https://www.pcronline.com/Courses/EuroPCR/EuroPCR-2017/Press
Abstracts are available online at https://www.pcronline.com/Courses/EuroPCR/EuroPCR-2017
Notes to Editors
What is EuroPCR?
EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional cardiovascular medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 11,500 participants every year, PCR organises annual courses in Singapore, London UK, Dubai EAU, Johannesburg RSA, Milan Italy, Chengdu China and Tokyo Japan.
For further information on EuroPCR, PCR London Valves, PCR Peripheral, PCR-CIT China Chengdu Valves, GulfPCR-GIM, AsiaPCR, AfricaPCR, PCR Tokyo Valves, and all PCR activities, please contact: Célia Vilà: firstname.lastname@example.org.
For more information, please visit: https://www.pcronline.com/Courses/EuroPCR/EuroPCR-2017 and follow us on Twitter https://twitter.com/PCRonline using the hashtag #EuroPCR